Johnson & Johnson is acquiring Halda Therapeutics for its lead program, a drug that recently posted encouraging Phase 1 data in advanced prostate cancer. This drug comes from a proprietary Halda platform technology that yields oral small molecules offering a novel mechanism for killing cancer cells.
The post J&J’s $3B Halda Acquisition Brings a Way to Overcome Drug Resistance in Prostate Cancer & More appeared first on MedCity News.
